Welcome to our dedicated page for Cypherpunk Technologies SEC filings (Ticker: CYPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cypherpunk Technologies Inc. (CYPH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Capital Market, Cypherpunk reports material events, capital structure changes, and governance decisions through current reports on Form 8-K and related exhibits.
In its 8-K filings, Cypherpunk has documented key steps in its transition from Leap Therapeutics, Inc. to Cypherpunk Technologies Inc., including actions approved at a special meeting of stockholders. One 8-K describes stockholder approval of an amendment to the certificate of incorporation to increase authorized share capital, a reverse stock split proposal, adoption of the 2025 Equity Incentive Plan, a private placement issuance proposal, and authorization to adjourn the meeting if needed. The same filing notes that Nasdaq confirmed the company had regained compliance with its minimum bid price listing requirement.
Another 8-K details a Waiver and Modification Agreement between Cypherpunk and Winklevoss Treasury Investments, LLC related to a warrant issued in connection with a private placement led by Winklevoss Capital. This filing explains how certain warrant share reservation requirements were waived to make shares available for potential issuance under the company’s at-the-market equity offering program and specifies conditions affecting when those warrant shares may be exercised.
Through these and other filings accessible via EDGAR, investors can review how Cypherpunk structures its equity incentives, manages authorized share levels, and documents financing arrangements tied to its Zcash-focused digital asset treasury strategy and ongoing operations. Stock Titan’s integration of real-time EDGAR updates and AI-powered summaries is designed to help readers quickly understand the implications of Cypherpunk’s 8-Ks, charter amendments, equity plans, and other SEC reports without having to parse every technical detail themselves.
Cypherpunk Technologies Inc. (CYPH)Gilead Sciences, Inc. covering its holdings of Cypherpunk common stock, par value $0.001 per share, CUSIP 52187K200.
Gilead now reports beneficial ownership of 0 shares of Cypherpunk common stock, representing 0% of the class, with no sole or shared voting or dispositive power. The filing states that Gilead's ownership is now "5 percent or less" of the class.
Gilead certifies that any securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cypherpunk, nor in connection with any transaction intended to have that effect.
Cypherpunk Technologies Inc. reported results of a special stockholder meeting and an update on its stock exchange listing. Stockholders approved a new 2025 Equity Incentive Plan that allows up to 31,454,785 shares of common stock to be covered by grants. They also approved amending the company’s charter to increase authorized shares from 250,000,000 to 500,000,000, with 490,000,000 designated as common stock and 10,000,000 as preferred stock, and to add clarifying language tied to Delaware law changes.
Stockholders further approved a reverse stock split proposal, a private placement issuance proposal, and the potential adjournment of the special meeting, with all measures receiving strong majorities. Separately, the company received notice from Nasdaq on December 11, 2025 that it had regained compliance with the minimum $1.00 bid price listing requirement, closing a prior deficiency matter.
Cypherpunk Technologies Inc. (CYPH) insiders reported an internal transfer of derivative securities. Winklevoss-affiliated entities filed a Form 4 showing an assignment of warrants5,616,906 shares of common stock. The warrants are exercisable immediately and expire on 10/08/2035, with an exercise price of
Following the transaction, the reporting persons indirectly beneficially own 57,182,378 warrants through Winklevoss Treasury Investments, LLC. Warrant exercises are limited so that the reporting group’s beneficial ownership does not exceed
CYPHERPUNK TECHNOLOGIES INC. insider Winklevoss-affiliated entities filed an initial Form 3 reporting significant ownership in CYPH. The filing shows indirect beneficial ownership of 8,283,761 shares of common stock held through Winklevoss Treasury Investments, LLC. It also reports a Pre-Funded Warrant exercisable for 75,448,618 shares of common stock at an exercise price of $0.001 per share, with no expiration date, and an additional Warrant for 62,799,284 shares at an exercise price of $0.5335 per share expiring on 10/08/2035.
Both the Pre-Funded Warrants and the Warrants are immediately exercisable but include a 19.99% beneficial ownership limitation, preventing exercises that would cause the reporting group and its affiliates to exceed 19.99% of CYPHERPUNK’s outstanding common stock after any exercise.
Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics) disclosed the initial beneficial ownership of securities by William McEvoy, who is a director, Chief Investment Officer and a 10% owner through affiliated Winklevoss-related entities. As of the reported event on 11/11/2025, he indirectly reports 8,283,761 common shares held by Winklevoss Treasury Investments and related entities.
Those entities also hold 75,448,618 pre-funded warrants, each exercisable for one common share at an exercise price of $0.001 per share, and 57,182,378 common warrants, each exercisable for one common share at an exercise price of $0.5335 per share, all acquired in an October 2025 private placement. Both warrant series are subject to a 19.99% beneficial ownership limitation, which restricts exercises that would take the holders above that ownership threshold after the private placement.
Cypherpunk Technologies Inc. has entered into a Waiver and Modification Agreement with Winklevoss Treasury Investments, LLC that changes how a large warrant can be used. Winklevoss Capital has waived the covenant requiring the company to reserve 57,182,378 shares of common stock solely for warrant exercise, allowing those shares to be available for potential offer, issue and sale under Cypherpunk’s previously announced at-the-market equity program of up to $200 million. In return, Winklevoss Capital cannot exercise the warrant for these 57,182,378 Restricted Warrant Shares until the fifth trading day after the earlier of the company increasing its authorized common stock to at least 490,000,000 shares or completing a reverse stock split of at least 1-for-5. The remaining warrant shares not designated as Restricted Warrant Shares are unaffected.
Cypherpunk Technologies Inc. (CYPH) director reported significant indirect share sales by affiliated investment entities. On November 17, 2025, HCV VIII Liquidating Trust sold 261,840 shares of common stock at a weighted average price of $3.14 per share, with individual trades ranging from $2.40 to $3.40, as part of its wind up and liquidation. On the same date, HealthCare Ventures IX, L.P. sold 414,479 shares at a weighted average price of $3.14 per share within the same price range, also tied to its liquidation.
Following these transactions, the reporting person is shown as indirectly beneficially owning 416,616 shares through related entities and 2,136 shares through Nine Capital Partners, plus 20,914 shares held directly. The filing notes that beneficial ownership of the fund and trust shares is disclaimed except for the reporter’s proportionate economic interest.
Cypherpunk Technologies Inc. director and reporting person filed a Form 4 after a significant share sale tied to a liquidating trust. On November 17, 2025, HCV VIII Liquidating Trust sold 261,840 shares of Cypherpunk common stock as part of the wind up and liquidation of that entity. The weighted average sale price was $3.14 per share, with individual trades reportedly occurring between $2.40 and $3.40 per share. Following the transaction, the reporting person shows 0 shares beneficially owned, held indirectly. The reporting person is a beneficiary of the HCV Liquidating Trust and may have been deemed to beneficially own the shares sold, but expressly disclaims beneficial ownership except for any proportionate pecuniary interest.
Cypherpunk Technologies Inc. director and senior officer Douglas E. Onsi filed a Form 4 reporting indirect sales of the company’s common stock on November 17, 2025. A liquidating trust, HCV VIII Liquidating Trust, sold 261,840 shares of common stock at a weighted average price of $3.14 per share, with individual trades ranging from $2.40 to $3.40, as part of its wind up and liquidation. On the same date, HealthCare Ventures IX, L.P. sold 414,479 shares of common stock at a weighted average price of $3.14 per share, also in connection with its wind up and liquidation, with trades in the same $2.40 to $3.40 range.
Following these transactions, Douglas E. Onsi reports 106,146 shares held directly, and indirect beneficial ownership of 416,616 shares and 2,136 shares through affiliated entities. He may be deemed to beneficially own the shares held or sold by these entities but disclaims beneficial ownership except to the extent of his proportionate pecuniary interest.